Lung Cancer, Non-Small Cell
Conditions
Keywords
Immunotherapeutic, Adjuvant cancer therapy, Non-small-cell lung cancer, ASCI
Brief summary
The purpose of this clinical trial is to find out how successfully non-small-cell lung cancer patients are able to give an immune response to injections of the immunotherapeutic product GSK1572932A, and to find out more about the safety of this treatment. A course of eight injections will be administered over 21 weeks; including screening for suitability and all tests, the duration of the study for a patient will be 30-35 weeks. During this period various tests will be performed, including physical examinations and blood tests. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Detailed description
This is an open, four-arm, parallel-group study, to be conducted at approximately 20 centers in Europe and Canada. All patients will receive the same immunotherapeutic treatment with GSK1572932A, but they will be recruited into four cohorts according to the details of their disease. Cohort 1: Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel. Cohort 2: Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy. Cohort 3: Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only. Cohort 4: Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only. Immunotherapeutic treatment will comprise eight doses of GSK1572932A. Doses will be administered at three-week intervals; in Cohort 1 this may be adapted to fit in with the patient's chemotherapy. During the study, adjuvant radiotherapy is allowed in Cohorts 1, 2 and 3 for patients in stage III only and is prohibited in Cohort 4. Chemotherapy during the study is allowed in Cohort 1 only as described above, and is prohibited in Cohorts 2-4. The total maximum duration of the study for a patient will be 30-35 weeks.
Interventions
BIOLOGICALImmunotherapeutic GSK1572932A
Intramuscular injection, 8 doses
DRUGCisplatin (CDDP)
Four cycles with doses based on patient's body surface area, intravenous administration
DRUGVinorelbine
Four cycles with doses based on patient's body surface area , intravenous administration
PROCEDURERadiotherapy
Regimen will be based upon the site's own standard procedures
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent obtained, * Aged 18 or more, * Pathologically proven stage IB, II or III NSCLC, * Tumor expresses MAGE-A3, * Free of distant metastasis, * For Cohort 1, all of the following: 1. Completely resected stage IB, II or IIIA NSCLC, 2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard 3. ECOG performance status = 0 or 1 4. Due to receive adjuvant chemotherapy as permitted in the protocol 5. Not received, not receiving, and not due to receive adjuvant radiotherapy (except stage III patients) 6. First administration of chemotherapy can be scheduled within 4-12 weeks after surgery * For Cohort 2, all of the following: 1. Resected stage IB, II or IIIA NSCLC, 2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard 3. ECOG PS = 0 or 1 4. Due to receive, or receiving, adjuvant chemotherapy as permitted in the protocol 5. Not received, not receiving, and not due to receive, adjuvant radiotherapy (except stage III patients) 6. First administration of ASCI treatment can be scheduled within 2-4 weeks after the last administration of chemotherapy 7. Received at least 2 cycles of standard chemotherapy before ASCI treatment is initiated, whereafter no further chemotherapy is planned * For Cohort 3, all of the following: 1. Resected stage IB, II or IIIA NSCLC 2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard 3. ECOG PS = 0 or 1 or 2 4. Not received, not receiving, and not due to receive, adjuvant chemotherapy 5. Not received, not receiving, and not due to receive, adjuvant radiotherapy (this does not apply to patients in stage III) 6. First administration of ASCI treatment can be scheduled within 4-8 weeks after surgery * For Cohort 4, all of the following: 1. Unresectable stage III NSCLC 2. ECOG PS = 0 or 1 or 2 3. Due to receive, or receiving, chemo- and radiotherapy according to institution standard 4. Received at least 2 cycles of standard chemotherapy before the initiation of ASCI treatment, whereafter no further chemo-/radiotherapy is planned 5. Stable disease or objective response (confirmed by CT scan) after standard chemo-/radiotherapy 6. Administration of ASCI treatment can be scheduled within 2-6 weeks after the last administration of chemo-/radiotherapy * Laboratory criteria: adequate bone-marrow reserve, adequate renal function, adequate hepatic function. * For females: EITHER not of child-bearing potential, OR sexually abstinent, OR negative urine pregnancy test + use of adequate contraceptive precautions from 30 days before first study treatment till 2 months after completion of study treatment course * In the view of the investigator, the patient can and will comply with the requirements of the protocol
Exclusion criteria
* Previous or concomitant other malignancies, except if effectively treated and considered by the investigator highly likely to have been cured * Pregnant or lactating * History of anaphylaxis or severe allergic reaction * Concurrent severe medical problems, unrelated to the malignancy, limiting full compliance with the study or exposing the patient to unacceptable risk * Psychiatric or addictive disorders compromising the ability to give informed consent, or to comply with the trial procedures * HIV-positive * Require treatment with systemic corticosteroids, or other immunosuppressive agents * Need home oxygenation * Received or plan to receive investigational or non-registered product other than the study medication from 30 days before first dose of study medication and during whole study period * History of chronic alcohol consumption and/or drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The anti-protein D seroconversion | After the fourth dose of ASCI and at the end of treatment |
| The anti-CpG seroconversion | After the fourth dose of ASCI and at the end of treatment |
| The MAGE-A3 cellular (T cell) response | After the fourth dose of ASCI and at the end of treatment |
| The anti-MAGE-A3 seroconversion | After the fourth dose of ASCI and at the end of treatment |
| Occurrence of adverse events, including abnormal hematological and biochemical laboratory values | During the study |
| Occurrence of serious adverse events | During the study |
Countries
Belgium, Canada, France, Germany, Italy, United Kingdom
Outcome results
None listed